Support & Care
Cure SMA Awards Grants to Four States to Expediate the Implementation of SMA Newborn Screening
With an incidence of approximately one in 11,000, more than 360 infants will be born annually with spinal muscular atrophy (SMA). Newborn screening can help […]
Read More ›Update on Cure SMA Summit of Strength Program – Gearing Up for 2020!
The 2019 Summit of Strength Program was a huge success, with more than 135 speakers sharing their expertise on numerous highly rated and unique topics. […]
Read More ›Check Out the Cure SMA Booklet on “Scientific Considerations for Drug Combinations”
There are now two treatments approved by the U.S. Food and Drug Administration (FDA) that target the underlying genetics of spinal muscular atrophy (SMA) and […]
Read More ›2019 Summit of Strength Program Continues its Success!
The 2019 Cure SMA Summit of Strength Program has had a fantastic first half, with over 50 speakers sharing their expertise on numerous unique topics. […]
Read More ›Cure SMA Newborn Screening Registry (NBSR)
In 2018, Spinal Muscular Atrophy (SMA) was added to the federal Recommended Uniform Screening Panel (RUSP), a panel of diseases that newborns in the United […]
Read More ›Zolgensma Update and Approval Webinars Now Available Online
A recording of last week’s webinar on Zolgensma updates is now available on Cure SMA’s YouTube channel. A presentation of the webinar can be found […]
Read More ›Cure SMA Awards Grants to Four States to Expediate the Implementation of SMA Newborn Screening
On July 3, 2018, Health and Human Services Secretary Alex Azar approved the recommendation that newborn screening for spinal muscular atrophy be implemented nationwide. This recommendation was […]
Read More ›Cure SMA Receives $150,000 Grant From the Oscar G and Elsa S Mayer Family Foundation
Cure SMA is pleased to announce receipt of $150,000 grant over three years, awarded by the Oscar G. and Elsa S. Mayer Family Foundation to […]
Read More ›Cure SMA Publishes Journal Article on Benefit-Risk Preferences in SMA
Your voice has been heard! Cure SMA has published a paper, titled, Evaluating Benefit-Risk Decision-Making in Spinal Muscular Atrophy: A First-Ever Study to Assess Risk Tolerance […]
Read More ›Cure SMA and Genentech Partner to Provide Travel Support to Adults with SMA the Annual SMA Conference
Cure SMA is thrilled to announce that we will be extending travel scholarship opportunities to adults with SMA (18 and over) who are attending the […]
Read More ›